A Global Leading Healthcare Technology Company Implements ValGenesis Cloud Solution for Validation Lifecycle Management
FREMONT, Calif., May 31, 2016 /PRNewswire/ -- ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS) is pleased to announce that an innovative Netherlands based global healthcare technology company went live with ValGenesis Validation Lifecycle Management System. The healthcare technology company, which offers high quality medical devices, patient monitoring products and accessories in over 100 countries made the choice to implement the ValGenesis Cloud Solution across their organization, so as to manage the validation process as 100% paperless.
Logo - http://photos.prnewswire.com/prnh/20160527/372959LOGO
ValGenesis VLMS provides a holistic view of the Validation process throughout the company with validation activities accessible in real-time from a convenient dashboard within ValGenesis. VLMS provides a direct line to validation tasks, inventory, work in progress, calendars, projects, reports, and a 360-degree view of GxP systems and assets by site. In addition, ValGenesis VLMS offers significant improvements to the current validation process in terms of increased efficiency, enforced data integrity, reduction in validation lifecycle times, improvements in regulatory compliance as well as a holistic view of validation projects. ValGenesis VLMS was selected to meet this global healthcare technology company's requirements with its out-of-the-box offering being implemented, validated and put into production in a short period of time.
Accessing ValGenesis VLMS through the enterprise-ready validated ValGenesis Cloud helps companies implement and deploy the system rapidly with less investment and in a shorter period of time. The ValGenesis Cloud solution is hosted in an SSAE 16 SOC 2 Type 2-certified data center, the most advanced infrastructure available. Through an independent evaluation, the hosted private ValGenesis Cloud has received a Service Organization Control 2 (SOC 2) Type 1 certification under AT Section 101.
"Our renowned customer is versatile in its innovation in the medical device industry and focuses on quality as a key driver for their success as well as for patients who benefit from their therapies," commented Dr. Siva Samy, ValGenesis' Chief Product Strategist. "ValGenesis is known for helping global companies manage the validation process electronically, reduce the validation cycle time, enable standardization, and enforce consistency and compliance in the corporate validation process. We are very pleased to partner with such a renowned organization and delighted to offer our SaaS support for their global validation needs."
About ValGenesis
ValGenesis, Inc. is the creator of an innovative software platform serving as the foundation for managing compliance-based validation activities in Life Sciences companies. ValGenesis, Inc. provides the first enterprise application to manage the corporate validation lifecycle process. As the only system for managing validation execution and approval 100% electronically, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award. The solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. For more information, visit www.valgenesis.com.
Media Contact:
Nancy DeFilippis
Email
510-445-0505 x1025
SOURCE ValGenesis, Inc.
Share this article